Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992484 | 0.92 | CNR2 (0.35) | GPR142GPR52MEN1KMT2ACNR2 | |
| SCHEMBL4986760 | 0.90 | EGLN1 (0.38) | GPR142MEN1KMT2AMAOBCNR2 | |
| SCHEMBL4988789 | 0.85 | CNR2 (0.44) | MEN1KMT2ACNR2 | |
| SCHEMBL4987057 | 0.84 | LMNA (0.44) | MEN1KMT2ACNR1 | |
| SCHEMBL4985987 | 0.84 | KDM4E (0.44) | GPR52 | |
| SCHEMBL4988103 | 0.83 | GPR183 (0.37) | MEN1KMT2ACNR2 | |
| SCHEMBL4983578 | 0.82 | CCR2 (0.36) | MEN1KMT2ACNR2 | |
| SCHEMBL5142384 | 0.81 | CNR2 (0.32) | KMT2ACNR2 | |
| SCHEMBL4982508 | 0.81 | L3MBTL1 (0.41) | MEN1KMT2ACNR2 | |
| SCHEMBL5142650 | 0.81 | CNR2 (0.38) | MEN1KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | GPR142 244/4885GPR52 124/4885MEN1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.